Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD) are two diseases that are common in the general population. To date, many studies have been conducted and demonstrate a direct link between NAFLD and CVD, but the exact mechanisms for this complex relationship are not well established. A systematic search of the PubMed database revealed that several common mechanisms are involved in many of the local and systemic manifestations of NAFLD and lead to an increased cardiovascular risk. The possible mechanisms linking NAFLD and CVD include inflammation, oxidative stress, insulin resistance, ectopic adipose tissue distribution, dyslipidemia, endothelial dysfunction, and adiponectin, among others. The clinical implication is that patients with NAFLD are at an increased risk of CVD and should undergo periodic cardiovascular risk assessment.

Liu H, Lu HY. Nonalcoholic fatty liver disease and cardiovascular disease. World J Gastroenterol 2014; 20(26): 8407-8415 Available from: URL: http://www.wjgnet.com/1007-9327/full/v20/i26/8407.htm DOI: http://dx.doi.org/10.3748/wjg.v20.i26.8407

Abstract

Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD) are two diseases that are common in the general population. To date, many studies have been conducted and demonstrate a direct link between NAFLD and CVD, but the exact mechanisms for this complex relationship are not well established. A systematic search of the PubMed database revealed that several common mechanisms are involved in many of the local and systemic manifestations of NAFLD and lead to an increased cardiovascular risk. The possible mechanisms linking NAFLD and CVD include inflammation, oxidative stress, insulin resistance, ectopic adipose tissue distribution, dyslipidemia, endothelial dysfunction, and adiponectin, among others. The clinical implication is that patients with NAFLD are at an increased risk of CVD and should undergo periodic cardiovascular risk assessment.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

Key words: Nonalcoholic fatty liver disease; Cardiovascular disease; Metabolic syndrome; Risk assessment

Core tip: The link between nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD) should be carefully evaluated in future research, which represents an intriguing field of investigation. A better understanding of the role of inflammation, oxidative stress, and insulin resistance, among other mechanisms, may be necessary to clarify the pathogenesis of NAFLD and CVD, and thereby contribute to the development of new therapies.

INTRODUCTION

Nonalcoholic fatty liver disease (NAFLD) is a common liver disease seen in clinical practice. It comprises a wide disease spectrum ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), which can progress to end stage liver disease, cirrhosis and hepatocellular carcinoma[1]. Initially, NAFLD was considered a benign liver disease, but it is now regarded as the liver manifestation of metabolic syndrome (MetS), a highly atherogenic condition. Most patients are overweight or obese with insulin resistance (IR), hypertension, and dyslipidemia. When compared with control subjects who do not have NAFLD, patients with NAFLD have a higher prevalence of atherosclerosis, which is independent of obesity and other established risk factors[2]. The role of NAFLD as a potential independent cardiovascular disease (CVD) risk factor has recently gained considerable prominence. The purpose of this review is to discuss the pathogenesis of NAFLD, the relationship between NAFLD and CVD, the mechanisms that link both conditions, and the clinical implications that may influence NAFLD and risk of CVD.
NAFLD, METS AND DIABETES

In general, NAFLD is diagnosed based on the following criteria: liver biopsy showing steatosis in at least 5% of hepatocytes or imaging study confirmation; exclusion of liver disease of other etiology, including alcohol-induced liver disease (history of excessive alcohol consumption greater than 20 g/d), drug-induced liver disease, autoimmune or viral hepatitis, as well as cholestatic or metabolic/genetic liver disease\(^{[3]}\). A joint interim statement of the International Diabetes Federation defines MetS with three of the five criteria, including elevated waist circumference, elevated triglycerides, reduced high-density lipoprotein (HDL), elevated blood pressure, and elevated fasting-glucose levels\(^{[3]}\). Approximately 90% of patients with NAFLD have at least one of the features of MetS, and approximately 33% meet the complete diagnosis, placing NAFLD as the hepatic representation of MetS\(^{[3]}\).

The prevalence of metabolic abnormalities such as diabetes and hypertension were increased up to 15-fold in patients with NASH compared to steatosis independent of age or body mass index (BMI). The relationship between diabetes and NAFLD remains poorly understood; thus, further prospective study of the association and outcomes should be performed. NAFLD predicts the development of type 2 diabetes mellitus (T2 DM) and vice versa, and each condition may serve as a progression factor for the other. In a recent study of T2 DM patients with an average BMI of 36 kg/m\(^2\), over 60% of patients who underwent weight reduction surgery (n = 64 of 92) had moderate to severe NAFLD on liver biopsy\(^{[3]}\). A study by Leite et al\(^{[3]}\) in patients with T2 DM found that three of the 92 patients had histological evidence of cirrhosis secondary to NAFLD without clinical evidence of liver disease. To approach the relationship between NAFLD and diabetes from another perspective, multiple studies supported by a recent meta-analysis have shown that NAFLD was associated with IR and diabetes and that NAFLD presence predicted the development of diabetes\(^{[3]}\). In a Korean study of 11091 individuals without diabetes at baseline, where fasting insulin levels were also measured and divided into quartiles, the 5-year (crude) OR for developing T2 DM in the presence of ultrasound evidence of fatty liver at baseline was 5.05 (95%CI: 2.08-12.29) for the lowest insulin quartile and was 6.34 (95%CI: 3.58-11.21) for the highest insulin quartile\(^{[3]}\). After multivariate adjustment, including for baseline glucose level, the OR for the highest insulin quartile remained significant at 2.42 (95%CI: 1.23-4.75)\(^{[3]}\).

NAFLD AND CARDIOVASCULAR DISEASE PREVALENCE

The clinical manifestations of NAFLD, such as steatosis and inflammation, are additional risk factors of CVD, although the precise mechanisms by which NAFLD contributes to CVD are still the subject of ongoing research. The age of onset of CVD events in NAFLD patients ranged from 45 to 65 years\(^{[3]}\). All had significantly higher estimated CVD risk at 10 years (17% vs 10%) by the Framingham risk score (FRS) than NAFLD patients without new CVD events\(^{[3]}\). The mortality rate among patients with NAFLD followed for 8 years was higher than that in the general population. In another study consisting of biopsy-diagnosed NAFLD patients who were followed for 18 years, CVD was among the common causes of death after all of the cancers combined\(^{[3]}\).

Clinical studies

Table 1 summarized several latest clinical studies on the relationship between NAFLD and CVD. Targher et al\(^{[3]}\)
showed a significant increase of atrial fibrillation (AF) in the presence of NAFLD (retrospective, n = 702, Caucasians). Lu et al\(^8\) suggested that NAFLD was a strong independent predictor of CVD and may play a central role in the cardiovascular risk of MetS. DeFilippis et al\(^8\) showed that CT-diagnosed NAFLD was associated with the atherogenic dyslipidemia phenotype in a dose-dependent fashion. These relationships persisted after adjustment for several metabolic risk factors and HOMA-IR, suggesting a possible independent pathophysiologic role between NAFLD and dyslipidemia (prospective, n = 3362, Caucasian, Chinese, African American, Hispanic). Feitosa et al\(^9\) showed that ALT (≥ 40 U/L) was a predictor of prevalent coronary heart disease (CHD) in men but not in women, while CT measured liver fat (FL) was not significant in either sex (prospective, n = 2756, European-American). Akın et al\(^{13}\) showed that obese children and adolescents with NAFLD are at an risk of early atherosclerotic changes. As liver function tests are not sufficient to identify patients with fatty liver, ultrasonographic evaluation of NAFLD might be considered in all obese children and adolescents (cross-sectional, n = 157, Turkey). Catena et al\(^{16}\) showed that in essential hypertensive patients without additional cardiovascular risk factors, NAFLD is associated with IR but not with increased arterial stiffness (observational, cross-sectional, n = 68, Italy). Colak et al\(^3\) showed that NAFLD is associated with earlier endothelial dysfunction in patients with atherosclerosis compared to control subjects (observational case-control, n = 51, Turkey). Based on the evidence enumerated above, NAFLD patients have higher incidence of AF, atherosclerotic changes, dyslipidemia and coronary heart disease. Therefore, our primary goal was to systematically evaluate the possible mechanisms linking NAFLD and CVD, their implication in clinical practice and various treatment modalities.

**Classical and new emerging risk factors**

The new risk factors for CVD include markers such as inflammation (e.g., C-reactive protein, lipoprotein A), homocysteine, and markers of fibrinolytic and homeostatic function (e.g., fibrinogen, tissue plasminogen activator, and plasminogen activator inhibitor-1 (PAI-1)). These markers are also associated with NAFLD\(^{13}\). A case-control study of 35 patients diagnosed with NAFLD by liver biopsy and 45 healthy controls showed that the plasma homocysteine level was higher in NAFLD patients compared to the control group (\(P = 0.0341\))\(^{16}\). The classic common risk factors for NAFLD and CVD are age and gender, physical inactivity, T2DM, hyperlipidemia, obesity, and hypertension\(^{10}\).

**POSSIBLE MECHANISMS LINKING NAFLD AND CVD**

The association of NAFLD with MetS and diabetes maybe partially explain the increased risk of CVD with NAFLD. Additionally, several studies showed that NAFLD in itself may contribute to the increased risk of CVD\(^{17-19}\). However, the exact mechanisms for this complex relationship are not clear. It is likely that several highly interrelated factors contribute to the enhanced risk of diabetes and metabolic syndrome in persons with NAFLD. The following factors are possible explanations of underlying mechanisms of the association between CVD and NAFLD.

**Oxidative stress and inflammation**

It has recently been shown that NAFLD is an independent risk factor for death from CVD. Although the precise mechanism linking NAFLD and CVD is unclear, a systematic review and meta-analysis have shown that a marker of NAFLD (and oxidative stress) may be the key link between NAFLD and CVD\(^{20}\). These data suggest that some component of oxidative stress, perhaps induced by the disease process in NAFLD, may be involved in the pathogenesis of CVD. Oxidative stress plays an important role in the progression from simple steatosis to steatohepatitis\(^{15}\). The association between oxidative stress and NAFLD in humans has been demonstrated by the immunohistochemical detection of lipid peroxidation products and 8-hydroxy-deoxyguanosine in the plasma and liver biopsies from patients with NAFLD\(^{21}\). Inflammation is crucial in the pathogenesis of NAFLD, and adipose tissue is now considered a metabolically active endocrine organ that produces pro-inflammatory cytokines, including TNF-\(\alpha\), IL-6, C-reactive protein (CRP) and IL-8. There is also evidence to support the activation of other inflammatory pathways, oxidative stress, as well as de novo pathways by TNF-\(\alpha\). A cross-sectional survey of 360 people indicated that an increase in CRP (OR = 1.37; 95\%CI: 1.06-1.77) per 1 SD (1.48 mg/L) was an independent risk factor for NAFLD\(^{21}\).

**IR**

Increased IR is an undisputed major contributor to NAFLD, MetS, and atherosclerosis. In fact, liver fat content appears to be the best independent predictor of IR in skeletal muscle, adipose tissue, and the liver\(^{22}\). Similarly, adverse CV outcome is likely to be associated with liver fat/inflammation in a monotonic relationship, progressively increasing with more advanced stages of NAFLD. While IR promotes fatty acid accumulation in the liver, the latter causes hepatic IR characterized by a lack of suppression of endogenous liver glucose production\(^{23}\). Therefore, NAFLD might act as a stimulus for further increased whole-body IR and dyslipidemia (with a characteristic overproduction of triglyceride- and cholesterol-rich remnant particles), leading to accelerated atherosclerosis\(^{11}\).

**Visceral fat**

Individuals with obesity have large amounts of visceral adipose tissue (VAT). VAT is a metabolically active endocrine organ that can secrete pro-inflammatory cytokines, adipokines and hormones that mediate inflammation
and IR, which, in turn, affect CV risk factors\cite{23}, VAT is defined as intra-abdominal fat bounded by parietal peritoneum or transversalis fascia. Recently, increased VAT assessed by CT showed a significant association with CVD, which was defined by the presence of plaque calcification\cite{24,25}. However, the mechanisms linking visceral fat or obesity to CV disease are strongly related to IR, which itself is robustly associated with CV risk and atherosclerosis, already reviewed in detail\cite{26}. It is therefore unclear whether VAT actually confers direct CV risk through secreted factors, or indirectly via IR-related processes, or both\cite{27}. Further studies to identify the association between NAFLD and CVD through VAT should be considered.

Ectopic adipose tissue distribution
In keeping with the adverse cardiovascular effects of ectopic hepatic fat, recent studies have also described the effects of ectopic fat accumulation in the heart, which correlates with visceral fat, IR and MetS parameters\cite{28}. Additionally, ectopic hepatic fat has been shown to be independently associated with NAFLD\cite{29}. In a recent meta-analysis of 16 studies (n = 2872), epicardial fat thickness or volume was significantly associated with the presence of coronary artery disease\cite{22,25}.

Adiponectin
Mature adipocytes act as an active endocrine and paracrine organ, secreting an increasing number of growth factors that participate in diverse metabolic processes, particularly IR\cite{30,31}. Patients with NAFLD exhibit reduced levels of adiponectin, which are inversely correlated with the severity of NAFLD histology\cite{32}. The reduced production of adiponectin associated with obesity may contribute to the progression of NAFLD\cite{33}.

Dyslipidaemia
Dyslipidaemia causes upregulation of the transcription factor sterol regulatory element binding protein-1c (SREBP-1c), and both insulin and SREBP-1c synergistically stimulate genes involved in de-novo lipogenesis. SREBP-1c also causes inhibition of FFA oxidation, leading to increased hepatic lipid content\cite{34,35}. To compensate for the increased hepatic triglycerides, the liver forms an atherogenic lipid profile, consisting of high TG levels, low high-density lipoprotein (HDL) cholesterol, increased small, dense low-density lipoprotein (LDL) particles, increased very low-density lipoprotein (VLDL) cholesterol levels and elevated apolipoprotein B100 concentration; all of which are strongly associated with adverse cardiovascular outcomes\cite{36,37}.

Postprandial hyperlipidemia
NAFLD may be linked to accelerated atherogenesis through the presence of abnormal lipoprotein metabolism, especially during the post-prandial phase\cite{38}. Postprandial hyperlipidemia is a risk factor for both NAFLD and CVD\cite{39,40}. The atherosclerotic risk of postprandial hyperlipidemia is derived from an increase of remnant lipoproteins (RLPs)\cite{41}. In patients with IR, an increase of postprandial RLP values usually occurs and becomes a risk factor for coronary heart disease\cite{42-44}. Swarbrick et al\cite{45} showed that consumption of fructose-sweetened, but not glucose-sweetened, beverages for 10 wk increases de novo lipid synthesis as well as the 24-h postprandial TG, which includes increased levels of apoB, LDL, oxidized LDL, RLP triglyceride, and the apoB/apoA1 ratio (all biomarkers were increased for CVD). Therefore, postprandial hyperlipidaemia may explain, at least in part, why some lean, overweight, and obese individuals with NAFLD may encounter CVD despite normal fasting lipid profiles or taking lipid-lowering medication\cite{46,47}.

Endothelial dysfunction
Endothelial dysfunction is now recognized as the earliest detectable component in the development of atherosclerosis. In both diabetic and non-diabetic cohorts, studies have shown an independent association between impaired endothelium-dependent flow-mediated dilation (FMD) and NAFLD. In addition, lower FMD was observed in NASH compared with simple steatosis, again confirming the graded association of CV risk with severity of NAFLD\cite{22,48}.

Chronic kidney disease
NAFLD may also be associated with a detrimental effect on other organs that may have a direct or indirect influence on CVD or organs that may accelerate the presentation of CVD\cite{49}. For example, NAFLD has been shown to be associated with the development of chronic kidney disease (CKD) in Korean individuals. Therefore, NAFLD may indirectly modulate the risk of CVD through CKD\cite{50}.

Obstructive sleep apnea
Obstructive sleep apnea (OSA) is characterized by loud and frequent snoring, periods of apnea during sleep, and excessive day somnolence\cite{51,52}. Interestingly, OSA is also regarded as one of the factors that accelerate the progression of NAFLD to NASH. Importantly, a considerable number of studies have shown an increase in the incidence of CVD in people with OSA. Animal studies have shown that OSA can lead to an increase in IR and alterations in lipid metabolism in the presence of NAFLD\cite{53}. The conclusion of that study was that OSA is associated with an increased risk of CVD, which has also been demonstrated in epidemiological, clinical and physiological studies\cite{22}.

Pro-coagulation and hypofibrinolysis
The prothrombotic state in the atherosclerosis process encompasses platelet hyper-aggregability, hypercoagulability and hyper-fibrinolysis\cite{54,55}. Markers of fibrinolytic and hemostatic function (e.g., fibrinogen, tissue plasminogen activator, and PAI-1-antigens) are strongly associated with NAFLD. PAI-1 is expressed in visceral adipose tis-
sue. Plasma PAI-1 levels are more closely related to fat accumulation and PAI-1 expression in the liver than in adipose tissue, suggesting that, among insulin-resistant individuals, fatty liver is an important site of PAI-1 production. Fibrinogen, von Willebrand factor (vWF) and PAI-1 are also considered markers of the acute-phase reaction of inflammation and thrombosis, and have been closely linked to CVD.\cite{7, 59-62}

**CLINICAL IMPLICATIONS**

It is evident that patients with NASH are more prone to developing CVD (increased mortality by 86%) than patients with simple steatosis (increased mortality by 55%). We suggest adding a new modality of approaching patients with NAFLD\cite{23}. The primary objective of any NAFLD therapy is to improve steatohepatitis and fibrosis, with the ultimate goal of preventing CVD and liver-related death.

Once the diagnosis of NAFLD is made, the first step will be a lifestyle intervention using a combination of diet, active walking, and behavior modification, with a goal of a 10% weight reduction\cite{10}. Recently, Koskinen et al\cite{63} showed that modest wine drinking (20-30 g/daily) offers protection against suspected NAFLD. Lifestyle modification remains the cornerstone of management. Weight loss and increased physical activity are effective mediators of NAFLD, and their role in CVD risk reduction is well established. However, before initiating any significant increase in exercise level, patients at risk should be evaluated for underlying CVD.

The second step is to assess the risk of hepatic fibrosis. The noninvasive methods for fibrosis evaluation include plasma cytokeratin 18 fragments and Angulo score\cite{9}. The invasive method (liver biopsy) remains the only reliable means to determine prognosis based on the severity of fibrosis.

The third step will include the assessment of cardiovascular risk stratification. We suggest the use of measurements of the carotid arteries (IMT) in non-diabetic NAFLD patients and/or the Framingham score with an effort test, as well as biomarkers of inflammation (C-reactive protein, fibrinogen), oxidative stress, (MDA, Paraoxonase), IR (HOMA), lipotoxicity (TG, HDL, LDL, TC), OGTT, and microalbumin/creatinine ratio\cite{13}.

The final step is to initiate appropriate therapy according to the comorbidities and the clinical status of each patient\cite{21} (Figure 1).

**Insulin sensitizers**

Metformin was associated with improvement in hepato-cellular ballooning, but not fibrosis, steatosis, inflammation or NAFLD activity score (NAS). TZDs should be reserved for second-line treatment in the majority of patients. One exception may be patients with T2DM and NAFLD in whom TZDM therapy may rectify both conditions. TZDs improved insulin sensitivity and steatohepatitis in a large, multicenter randomized controlled trial Pioglitazone or Vitamin E for NASH Study (PIVENS). However, we should notice its drawback of lower extremity edema and weight gain (average 2 to 5 kg).

**Incretin-based therapies**

A direct relationship between the gastrointestinal and
endocrine systems has recently been appreciated with the discovery of neuroendocrine hormones known as incretins. The two primary incretins are GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). There is accumulating and convincing pre-clinical evidence that GLP-1 and its analogues have the ability to decrease hepatic steatosis in animal models, suggesting that there is potential for incretin-based medications to reverse or delay progression through the stages of NAFLD to cirrhosis\(^{[64]}\). There is an urgent need for prospective clinical trials designed to scrutinize the potential of these agents for treatment of NAFLD beyond improvements in metabolic parameters, such as weight loss.

**Cytoprotective and antioxidant agents**

Two randomized trials\(^{[65,66]}\) showed that high-dose bile acids are unlikely to provide significant benefit, although their use was routinely advocated. Two recently published, large, randomized controlled trials, PIVENS and TONIC\(^{[67,68]}\), assessed the effect of vitamin E on adult and pediatric NAFLD populations, respectively. Vitamin E treatment resulted in improvements in hepatocellular ballooning and NAS in both trials. These results for vitamin E are quite promising and suggest that patients with biopsy-proven steatohepatitis associated with hepatocellular ballooning (NAS ≥ 4) may benefit from its use.

**Antitumour necrosis factor-alpha agents**

This type of therapy has been studied in a number of small NAFLD trials, two of which have assessed the effect of vitamin E on adult and pediatric NAFLD populations, respectively. Vitamin E treatment resulted in improvements in hepatocellular ballooning and NAS in both trials. These results for vitamin E are quite promising and suggest that patients with biopsy-proven steatohepatitis associated with hepatocellular ballooning (NAS ≥ 4) may benefit from its use.

**Lipid-lowering agents**

One recently published large study\(^{[69]}\) provided compelling evidence that lipid-lowering agents, such as statins, are safe and efficacious in patients with NAFLD/NASH and that the agents can induce a reduction in the extent of the hepatic steatosis.

**Phlebotomy**

One prospective phase II study\(^{[70,71]}\) of phlebotomy with paired liver biopsies that evaluated phlebotomy therapy in NAFLD patients suggested that iron reduction may improve liver histology.

**Surgical intervention and anti-obesity drugs**

Bariatric surgery is an increasingly popular therapeutic option among morbidly obese patients. One recently published study\(^{[72]}\) reported that surgery should complement treatment of obesity-related comorbidity, but not replace established therapy:

Theoretically, improving NAFLD via weight loss is an ideal approach in obese or overweight people because other complications are simultaneously ameliorated with weight loss. Of several commonly used antiobesity medications, orlistat and sibutramine are available for long-term prescription. Harrison\(^{[73]}\) reported that subjects who lost ≥ 5% of their body weight over 9 mo experienced improvements in IR and steatosis, while subjects who lost ≥ 9% of their body weight also experienced improvements in hepatic histology\(^{[74,75]}\). Both orlistat and sibutramine have been shown to have beneficial effects on body weight, lipid profiles, glucose metabolism, and inflammatory markers in several trials\(^{[76]}\). However, insufficient safety data are available regarding the long-term outcomes of antiobesity therapy. Indeed, sibutramine was reported to increase blood pressure and heart rate, which may limit its use in clinical practice\(^{[77]}\).

**CONCLUSION**

NAFLD is regarded as the hepatic component of metabolic syndrome and is associated with a high risk of developing CVD. Oxidative stress, inflammation dyslipidemia, IR, visceral fat, low adiponectin, ectopic adipose tissue distribution, endothelial dysfunction and postprandial dyslipidemia are the main factors that lead to and further aggravate the course of NAFLD, as well as accelerate the progress of atherosclerosis and development of CVD. NAFLD patients should be considered candidates not only for aggressive treatment of their liver disease but also for careful monitoring and potential treatment of underlying CVD risk factors because many patients with NAFLD will have major CVD events and die prior to the development of advanced liver disease.

**REFERENCES**

1. Hashizume H, Sato K, Yamazaki Y, Horiguchi N, Kakizaki S, Mori M. A prospective study of long-term outcomes in female patients with nonalcoholic steatohepatitis using age- and body mass index-matched cohorts. Acta Med Okayama 2013; 67: 45-53 [PMID: 23495086 DOI: 10.1111/j.1478-3231.2011]
2. Blackett PR, Sanghera DK. Genetic determinants of cardio-metabolic risk: a proposed model for phenotype association and interaction. J Clin Lipidol 2013; 7: 65-81 [PMID: 23535885 DOI: 10.1016/j.jcllip.2012.04.079]
3. Nestel PJ, Mensink RP. Perspective: nonalcoholic fatty liver disease and cardiovascular risk. Curr Opin Lipidol 2013; 24: 1-3 [PMID: 23298957 DOI: 10.1097/MOL.0b013e32835c834]
4. Williams KH, Shackell NA, Gorrell MD, McLennan SV, Twigg SM. Diabetes and nonalcoholic fatty liver disease: a pathogenic duo. Endocr Rev 2013; 34: 84-129 [PMID: 23288855 DOI: 10.1210/er.2012-1009]
5. Kucukazman M, Ata N, Yavuz B, Dal K, Sen O, Deveci OS, Agliadioglou K, Yeniho AO, Nazligul Y, Ertegrul DT. Evaluation of early atherosclerosis markers in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2013; 25: 147-151 [PMID: 23085576]
6. Gökçe S, Atiwinic Z, Aycan Z, Cinar HG, Zorlu P. The relationship between pediatric nonalcoholic fatty liver disease and cardiovascular risk factors and increased risk of atherosclerosis in obese children. Pediatr Cardiol 2013; 34: 308-315 [PMID: 22875138 DOI: 10.1007/s00246-012-0447-9]
7. Leite NC, Villela-Nogueira CA, Pannain VL, Bottino AC, Rezende GF, Cardoso CR, Salles GF. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabete: prevalences and correlated factors. Liver Int 2011; 31: 700-706 [PMID: 21457442 DOI: 10.1111/j.1478-3231.2011]
8. Lu H, Liu H, Hu F, Zou L, Luo S, Sun L. Independent Asso-
cation between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: A Systematic Review and Meta-Analysis. Int J Endocrinol 2013; 2013: 124958 [PMID: 23596966 DOI: 10.1155/2013/124958]

10. DeFilippis AP, Blaha MJ, Martin SS, Reed RM, Jones SR, Nasir K, Blumenthal RS, Budoff MJ. Nonalcoholic fatty liver disease and serum lipoproteins: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 2013; 227: 429-436 [PMID: 23419204 DOI: 10.1016/j.atherosclerosis.2013.01.013]

11. Feitosa MF, Reiner AP, Wojczynski MK, Graff M, North KE, Carr JJ, Boreckii IB. Sex-influenced association of nonalcoholic fatty liver disease with coronary heart disease. Atherosclerosis 2013; 227: 420-424 [PMID: 23599092 DOI: 10.1016/j.atherosclerosis.2013.01.013]

12. Akin L, Kurtoglu S, Yikilmaz A, Kendirci M, Elmali F, Mazcioglu M. Fatty liver is a good indicator of subclinical atherosclerosis risk in obese children and adolescents regardless of liver enzyme elevation. Acta Paediatr 2013; 102: e107-e113 [PMID: 23190373 DOI: 10.1111/apa.12099]

13. Huang Y, Bi Y, Xu M, Ma Z, Xu Y, Wang T, Li M, Liu Y, Lu J, Chen Y, Huang F, Xu B, Zhang J, Wang W, Li X, Nong G. Nonalcoholic fatty liver disease is associated with atherosclerosis in middle-aged and elderly Chinese. Arterioscler Thromb Vasc Biol 2012; 32: 2321-2326 [PMID: 22941750 DOI: 10.1161/ATVBAHA.112.252957]

14. Catena C, Bernardi S, Sabato N, Grillo A, Ermani M, Sechi LA, Fabris B, Carretta R, Fallo F. Ambulatory arterial stiffness indices and non-alcoholic fatty liver disease in essential hypertension. Nutr Metab Cardiovasc Dis 2013; 23: 389-393 [PMID: 22796347 DOI: 10.1016/j.numecd.2012.05.007]

15. Colak Y, Senates E, Yesil A, Yilmaz Y, Ozturk O, Doganay L, Coskunpinar E, Kahraman OT, Mesci B, Ulusoglu C, Tuncer I. Assessment of endothelial function in patients with nonalcoholic fatty liver disease. Endocrine 2013; 43: 100-107 [PMID: 22661277]

16. de Carvalho SC, Muniz MT, Siqueira MD, Siqueira ER, Gomes AV, Silva KA, Bezerra LC, D’Almeida V, de Oliveira CP, Pereira LM. Plasmatic higher levels of homocysteine in non-alcoholic fatty liver disease (NAFLD). Nutr J 2013; 12: 37 [PMID: 24050789 DOI: 10.1186/1475-2891-12-37]

17. Thakur ML, Sharma S, Kumar A, Bhatt SP, Luthra K, Sonmez A. Elevated asymmetric dimethylarginine in plasma: an early marker for endothelial dysfunction in non-alcoholic fatty liver disease? Nutr J 2013; 12: 94-95 [PMID: 23245962 DOI: 10.1186/1475-2891-12-94]

18. Li G, Hu H, Shi W, Li Y, Liu L, Chen Y, Hu X, Wang J, Gao J, Yin D. Elevated hematocrit in nonalcoholic fatty liver disease: a potential cause for the increased risk of cardiovascular disease? Clin Hemorheol Microcirc 2013; 52: 605-613 [PMID: 22271511 DOI: 10.1002/hep.25593]

19. Stepanova M, Younossi ZM. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol 2012; 10: 646-650 [PMID: 22245962 DOI: 10.1016/j.cgh.2011.12.039]

20. Kim D, Choi SY, Park EH, Lee W, Kang JH, Kim W, Kim YJ, Yoon JH, Jeong SH, Lee DH, Lee HS, Larson J, Therneau TM, Kim WR. Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology 2012; 56: 605-613 [PMID: 22271511 DOI: 10.1002/hep.25593]

21. Porcarelli L, De Simone F, Curzen NP, Byrne CD. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur Heart J 2012; 33: 1190-1200 [PMID: 22408306 DOI: 10.1093/euheartj/het453]

22. Chatterah H, Vuppalanchi R, Chalasani N. Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis 2012; 32: 22-29 [PMID: 22418885 DOI: 10.1055/s-0032-1306423]

23. Tereprasertsuk S, Leather S, Adams LA, Lindor KD, St Sauver J, Angulo P. The Framingham risk score and heart disease in nonalcoholic fatty liver disease. Liver Int 2012; 32: 945-950 [PMID: 22299654 DOI: 10.1111/j.1478-3231.2011.02753.x]

24. Ma J, Guo B, Fu J, Zhang X, Zhou Y, Wang X, Zhang Q, Li L, Zhang Q, Wang S, Wang X, Ge Y, Chen H, Wang J, Huang Y. Nonalcoholic fatty liver disease and diabetes. Diabetes Res Clin Pract 2012; 98: 47-52 [PMID: 22189171 DOI: 10.1016/j.diabres.2011.11.022]

25. Alkhouri N, Kistangari G, Campbell C, Lopez R, Zein NN, Feldstein AE. Mean platelet volume as a marker of increased cardiovascular disease risk in patients with nonalcoholic steatohepatitis. Hepatology 2012; 55: 331 [PMID: 21969091 DOI: 10.1002/hep.24721]

26. Motta AB. Report of the international symposium: polycystic ovary syndrome: first Latin-American consensus. Int J
July 14, 2014 | Volume 20 | Issue 26

Liu H et al. NAFLD and CVD

Clin Pract 2010; 64: 544-557 [PMID: 20456209 DOI: 10.1111/j.1742-1241.2009.02259.x]

39 Gawrieh S, Baye TM, Carless M, Wallace J, Komorowski R, Kleiner DE, Andrus D, Makladi B, Cole R, Charlton M, Curran J, Dyer TD, Charlesworth J, Wilke N, Blangero J, Kisselbahr AH, Ollivier M. Hepatic gene networks in morbidity obese patients with nonalcoholic fatty liver disease. Obes Surg 2010; 20: 1698-1709 [PMID: 20473581 DOI: 10.1007/s11695-010-0171-6]

40 Hessheimer AJ, Forner A, Varela M, Bruix J. Metabolic risk factors are a major comorbidity in patients with cirrhosis independent of the presence of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2010; 22: 1239-1244 [PMID: 2085515 DOI: 10.1097/MEG.0b013e82833aa196]

41 Lee YJ, Shim JY, Moon BS, Shin YH, Jung DH, Lee JH, Lee HR. The relationship between arterial stiffness and nonalcoholic fatty liver disease. Dig Dis Sci 2012; 57: 196-203 [PMID: 21750292 DOI: 10.1007/s10620-011-1819-3]

42 Ahmed MH, Barakat S, Almobarak AO. Nonalcoholic fatty liver disease and cardiovascular disease: has the time come for cardiologists to be hepatologists? J Obes 2012; 2012: 683:315. [DOI: 10.1155/2012/683315]

43 Hurjui DM, Nita O, Graur M, Mihalache L, Popescu DS, Hutanau IC, Ungureanu D, Graur M. Non-alcoholic fatty liver disease is associated with cardiovascular risk factors of metabolic syndrome. Rev Med Chir Soc Med Nat Iasi 2012; 116: 692-699 [PMID: 23272512]

44 Cameron I, Alam MA, Wang J, Brown L. Endurance exercise in a rat model of metabolic syndrome. Can J Physiol Pharmacol 2012; 90: 1490-1497 [PMID: 23078220 DOI: 10.1139/y2012-097]

45 Santos RD, Agewall S. Non-alcoholic fatty liver disease and cardiovascular disease. Atherosclerosis 2012; 224: 324-325 [PMID: 22840429 DOI: 10.1016/j.atherosclerosis.2012.07.018]

46 Hurjui DM, Nita O, Graur M, Mihalache L, Popescu DS, Graur M. The central role of the non alcoholic fatty liver disease in metabolic syndrome. Rev Med Chir Soc Med Nat Iasi 2011; 116: 425-431 [PMID: 23077931]

47 Swarbrick MM, Stanhope KL, Elliott SS, Graham JL, Krauss RM, Christiansen MP, Griffen SC, Keim NL, Havel PJ. Consumption of fructose-sweetened beverages for 10 weeks increases postprandial triacylglycerol and apolipoprotein-B concentrations in overweight and obese women. Br J Nutr 2008; 100: 947-952 [PMID: 18384705 DOI: 10.1017/ S0007114508007052]

48 Senates E, Colak Y, Yesil A, Cokşunpinar E, Sahin O, Kabraman OT, Erkalma Şenateş B, Tuncer I. Circulating resistin protein-B concentrations in overweight and obese women. Pak J Biol Sci 2012; 15: 401-406 [PMID: 23352496]

49 Fan JG, Zhou Q, Wo QH. [Effect of body weight mass and its change on the incidence of nonalcoholic fatty liver disease]. Zhonghua Gan Zang Bing Zazhi 2010; 18: 676-679 [PMID: 20943079 DOI: 10.3766/cma.j.issn.1007-3418.2010.09.008]

50 Rivera R, Vanclocha F. [Nonalcoholic fatty liver disease and psoriasis]. Actas Dermosifiliogr 2010; 101: 657-658 [PMID: 20965008]

51 Ashburn DD, Reed MJ. Gastrointestinal system and obesity. Crit Care Clin 2010; 26: 625-627 [PMID: 20970047 DOI: 10.1016/j.ccc.2010.06.006]

52 Roitberg GE, Sharkhun OO, Ushakova TI. [Non-alcoholic fatty liver disease as an atherosclerosis risk factor]. Ekop Klin Kardiol 2010; (7): 20-24 [PMID: 21035079]

53 Kwon YM, Oh SW, Hwang SS, Lee C, Kwon H, Chung GE. Association of nonalcoholic fatty liver disease with components of metabolic syndrome according to body mass index in Korean adults. Am J Gastroenterol 2012; 107: 1852-1858 [PMID: 23059280 DOI: 10.1038/ajg.2012.314]

54 Băloaneau CI, Strea CT, Vere CC, Comănescu V, Rogoveanu I. Association between liver histology, carotid ultrasonography and retinal vascular changes in patients with nonalcoholic fatty liver disease (NAFLD). Rom J Morphol Embryol 2012; 53: 609-614 [PMID: 22990555]

55 Kubes P, Mehal WZ. Sterile inflammation in the liver. Gas- troenterology 2012; 143: 1158-1172 [PMID: 22982943 DOI: 10.1053/j.gastro.2012.09.008]

56 Li X, Xia M, Ma H, Hofman A, Hu Y, Yan H, He W, Lin H, Jeekel J, Zhao N, Gao J, Gao X. Liver fat content is associated with increased carotid atherosclerosis in a Chinese middle-aged and elderly population: the Shanghai Changfeng study. Atherosclerosis 2012; 224: 480-485 [PMID: 22884916 DOI: 10.1016/j.atherosclerosis.2012.07.002]

57 Yang YY, Huang YT, Lee TY, Chan CC, Yeh YC, Lee KC, Lin HC. Rho-kinase-dependent pathway mediates the hepatoprotective effects of sorafenib against ischemia/reperfusion liver injury in rats with nonalcoholic steatohepatitis. Liver Transpl 2012; 18: 1371-1383 [PMID: 22847887 DOI: 10.1002/lt.23520]

58 Saleh DA, Ismail MA, Ibrahim AM. Non alcoholic fatty liver disease, insulin resistance, dyslipidemia and atherogenic ratios in epileptic children and adolescents on long term antiepileptic drug therapy. Pak J Biol Sci 2012; 15: 68-77 [PMID: 22545359]

59 Ampuero J, Romero-Gómez M. [Influence of non-alcoholic fatty liver disease on cardiovascular disease]. Gastroenterol Hepatol 2012; 35: 585-593 [PMID: 22541252 DOI: 10.1016/j.gastro.2012.02.005]

60 Mantovani A, Zoppini G, Targher G, Golia G, Bonora E. Non-alcoholic fatty liver disease is independently associated with left ventricular hypertrophy in hypertensive Type 2 diabetic individuals. J Endocrinol Invest 2012; 35: 215-218 [PMID: 22909991]

61 Koskinen J, Magnusson CG, Kähönen M, Loo BM, Marinm J, Jula A, Saarikoski LA, Huupponen R, Viikari JS, Raitakari OT, Juonala M. Association of liver enzymes with metabolic syndrome and carotid atherosclerosis in young adults. The Cardiovascular Risk in Young Finns Study. Ann Med 2012; 44: 187-195 [PMID: 21254896 DOI: 10.3109/07853739.2010.532152]

62 Samson SL, Bajaj M. Potential of incretin-based therapies for non-alcoholic fatty liver disease. J Diabetes Complications 2013; 27: 401-406 [PMID: 23522496]

63 Leuschner UF, Lindenthal B, Herrmann G, Arnold JC, Rösle M, Cordes HJ, Zeuzem S, Hein J, Berg T. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology 2010; 52: 472-479 [PMID: 20683947 DOI: 10.1002/hep.23277]

64 Ratzu V, de Ledinghen V, Oberli F, Mathurin P, Wartelle-Bladou C, Renou C, Sogni P, Maynard L, Larrey D, Serfaty L, Bonnefont-Rousselot D, Bastard JP, Rivière M, Spérand J. A randomized controlled trial of high-dose ursodeoxycholic acid for nonalcoholic steatohepatitis. J Hepatol 2011; 54: 1011-1019 [PMID: 21145828 DOI: 10.1016/j.jhep.2010.08.030]

65 Sanjal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuenschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR. Pioglitazone, vitamin E, or place-
bo for nonalcoholic steatohepatitis. *N Engl J Med* 2010; 362: 1675-1685 [PMID: 20427778 DOI: 10.1056/NEJMoa0907929]

68 Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, Abrams SH, Scheiman AO, Sanyal AJ, Chalasani N, Tonascia J, Unalp A, Clark JM, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. *JAMA* 2011; 305: 1659-1668 [PMID: 21521847 DOI: 10.1001/jama.2011.520]

69 Adams LA, Zein CO, Angulo P, Lindor KD. A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. *Am J Gastroenterol* 2004; 99: 2365-2368 [PMID: 15571584]

70 Satapathy SK, Sakhija P, Malhotra V, Sharma BC, Sarin SK. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. *J Gastroenterol Hepatol* 2007; 22: 634-638 [PMID: 17444848]

71 Nseir W, Mograbi J, Ghali M. Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies. *Dig Dis Sci* 2012; 57: 1773-1781 [PMID: 22419057 DOI: 10.1007/s10620-012-2118-3]

72 Dixon JB. Surgical management of obesity in patients with morbid obesity and nonalcoholic fatty liver disease. *Clin Liver Dis* 2014; 18: 129-146 [PMID: 24274869]

73 Beaton MD, Chakrabarti S, Levstik M, Speechley M, Marotta P, Adams P. Phase II clinical trial of phlebotomy for non-alcoholic fatty liver disease. *Aliment Pharmacol Ther* 2013; 37: 720-729 [PMID: 23441892 DOI: 10.1111/apt.12255]

74 Harrison AG. Fragmentation reactions of methionine-containing protonated octapeptides and fragment ions therefrom: an energy-resolved study. *J Am Soc Mass Spectrom* 2013; 24: 1555-1564 [PMID: 23943431 DOI: 10.1007/s13361-013-0706-x]

75 Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. *Hepatology* 2009; 49: 80-86 [PMID: 19053049 DOI: 10.1002/hep.22575]

76 Tzialamos K, Krassas GE, Tzotzas T. The use of sibutramine in the management of obesity and related disorders: an update. *Vasc Health Risk Manag* 2009; 5: 441-452 [PMID: 19475780]

77 Filippatos TD, Derdemozis CS, Gazi IF, Nakou ES, Mikhailidis DP, Elisaf MS. Orlistat-associated adverse effects and drug interactions: a critical review. *Drug Saf* 2008; 31: 53-65 [PMID: 18095746]
